The pharmaceutical giant AbbVie has closed its 2025 fiscal year by posting a record $61.2 billion in revenue, surpassing the consensus forecast from market analysts. The company’s strategic pivot is proving effective, as its newer, high-growth medications increasingly offset the steep decline in sales of its former flagship drug, Humira. Investors are now focusing on the firm’s confident guidance for the current year.
A Confident Start to 2026
Management has issued an optimistic forecast for 2026, projecting adjusted earnings per share (EPS) in a range of $14.37 to $14.57. The company is targeting top-line growth of approximately 9.5%, which would bring total revenue to around $67 billion. To bolster long-term competitiveness, AbbVie also announced plans to invest roughly $100 billion over the next decade in U.S.-based research, development, and capital projects.
Immunology Portfolio Drives Strong Finish
AbbVie’s performance in the final quarter of 2025 was a key contributor to the annual record. Net revenue reached $16.62 billion, marking a 6.6% increase from the same period a year earlier and exceeding analyst estimates of $16.39 billion. Adjusted EPS of $2.71 also came in six cents above market expectations.
Should investors sell immediately? Or is it worth buying AbbVie?
The immunology segment was the cornerstone of this success, generating $30.4 billion for the full year. The drugs Skyrizi and Rinvoq have become reliable growth engines, effectively compensating for Humira’s substantial revenue loss following its patent expiration. In the fourth quarter alone, Skyrizi contributed $5 billion, while Rinvoq added nearly $2.4 billion to the total.
Segment Performance Shows Varied Results
While neuroscience also delivered robust growth, supported in part by migraine treatments, other business areas faced specific headwinds:
- Aesthetics: Global economic pressures softened demand, particularly for filler products.
- Oncology: Company leadership anticipates increased pricing pressure in 2026 due to regulatory changes stemming from the U.S. Inflation Reduction Act.
- Research & Development: Full-year results were impacted by significant expenditures related to acquired in-process R&D and milestone payments.
Market Context
AbbVie shares recently traded at $217.11. Despite the solid operational performance, the Relative Strength Index (RSI) reading of 16.8 indicates the stock is currently in a technically oversold position according to that metric.
Ad
AbbVie Stock: Buy or Sell?! New AbbVie Analysis from February 5 delivers the answer:
The latest AbbVie figures speak for themselves: Urgent action needed for AbbVie investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 5.
AbbVie: Buy or sell? Read more here...
